Last Month in Oncology with Dr. Bishal Gyawali: April 2019
By BISHAL GYAWALI, MD
Keynote speech on the JAVELIN not going far enough to improve survival
The treatment landscape for metastatic renal-cell carcinoma has changed dramatically with the introduction of immunotherapies. Unfortunately though, we are promoting combinations over single agents without having much idea of added benefit of each drug. This is an important issue because when we combine two drugs, the only thing we are certain of are the added toxicities. PD-1 inhibitor nivolumab had improved OS when given in second line, however nivolumab was tested in combination with ipilimumab (not as a nivolumab monotherapy) in the first line trial. Now, pembrolizumab and avelumab have followed suit, although their combination partner was axitinib – a VEGF inhibitor. The control arm was sunitinib for both of the trials of pembrolizumab plus axitinib (KEYNOTE 426) and avelumab plus axitinib (Javelin 101). This is a little surprising because we are testing A B versus C, where both A and B haven’t been approved for the given setting – axitinib was approved for RCC in second line. Both these combinations improved PFS versus sunitinib but only the pembrolizumab combination has shown improved OS. However, I have doubts about the contribution of axitinib to these results. What would the outcome be if pembrolizumab alone is followed by sunitinib in second line? It is important to note that only one third of patients who discontinued sunitinib received PD-1 inhibitor s...
Source: The Health Care Blog - Category: Consumer Health News Authors: Christina Liu Tags: Medical Practice Physicians Bishal Gyawali Clinical Trials Oncology PD-1 inhibitor Source Type: blogs
More News: Blogging | Bone Cancers | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Colorectal Cancer | Harvard | Health | Health Management | Hepatocellular Carcinoma | History of Medicine | Immunotherapy | Kidney Cancer | Liver Cancer | Mania | Myeloma | Osteosarcoma | Radiation Therapy | Renal Cell Carcinoma | Sarcomas | Soft Tissue Sarcoma | Study | Toxicology | Women | Yervoy